混合示踪剂吲哚菁绿-99mTc-纳米胶体用于膀胱癌前哨淋巴结活检的前瞻性初步研究评价
这项前瞻性初步研究纳入20例拟行根治性膀胱切除联合前哨淋巴结活检及扩大盆腔淋巴结清扫的肌层浸润性膀胱癌cN0M0患者,术前经膀胱肿瘤/瘢痕周围四点注射吲哚菁绿-99mTc-纳米胶体后行淋巴显像与SPECT/CT,术中在放射引导与荧光引导下切除前哨淋巴结。19例可分析,术前影像在10例(53%)中识别出前哨淋巴结,其中20%显示扩大盆腔淋巴结清扫范围外的引流途径;作者认为该混合示踪剂用于膀胱癌前哨淋巴结活检可行。
要点
- 术前影像可在53%(10/19)患者中识别前哨淋巴结,平均每例1.6枚。
- 术前影像在20%患者中显示扩大盆腔淋巴结清扫范围外的引流途径。
- 2例(10%)术前未显影者在术中显示荧光及放射性前哨淋巴结。
核心结论
- 使用混合示踪剂吲哚菁绿-99mTc-纳米胶体的膀胱癌前哨淋巴结活检是可行的,术前影像对83%显示前哨淋巴结的患者中能否实施前哨淋巴结活检具有预测价值。
- 在淋巴显像与SPECT/CT术前前哨淋巴结定位成功的患者中,术中前哨淋巴结引导与检测有效,即使在扩大盆腔淋巴结清扫区域外亦然。
- 作者认为本研究凸显了术前影像在具挑战性的影像引导手术应用中的关键作用。
研究设计与样本
- 前瞻性初步研究,纳入20例组织学确诊的cN0M0肌层浸润性膀胱癌患者(平均年龄63.3岁,范围30-82岁),拟行根治性膀胱切除联合前哨淋巴结活检及扩大盆腔淋巴结清扫。
- 其中12例在 neoadjuvant chemotherapy 后手术;患者于根治性膀胱切除前一天接受膀胱逼尿肌内肿瘤/瘢痕周围4点注射吲哚菁绿-99mTc-纳米胶体(平均208 MBq,范围172-229 MBq),随后行淋巴显像与SPECT/CT。
- 前哨淋巴结切除在放射引导与荧光引导下进行;19例可分析。
主要发现
- 术前影像在10例患者(53%;平均每例1.6枚前哨淋巴结)中识别出前哨淋巴结,并在20%患者中显示扩大盆腔淋巴结清扫范围外的引流途径。
- 2例(10%)术前未显影的患者在术中显示荧光及放射性前哨淋巴结;原发肿瘤位于膀胱左侧壁附近似乎是未显影的一个因素。
- 扩大盆腔淋巴结清扫的淋巴结获取数各患者不同(平均23.3枚);组织病理学证实4例(21%)患者淋巴结阳性。
- 在可识别前哨淋巴结的2例患者中,扩大盆腔淋巴结清扫标本为肿瘤阴性;所有淋巴结阳性患者均为晚期病变(III期)。
关键数值与推荐
- 术前影像识别前哨淋巴结的患者比例为53%(10/19),平均每例1.6枚。
- 术前影像显示扩大盆腔淋巴结清扫范围外引流途径的患者比例为20%。
- 术前未显影但术中显示荧光及放射性前哨淋巴结的患者比例为10%(2例)。
- 组织病理学证实淋巴结阳性的患者比例为21%(4例),均为III期。
临床怎么用
- 作者认为,在术前淋巴显像与SPECT/CT前哨淋巴结定位成功的患者中,术中前哨淋巴结引导与检测有效,即使在扩大盆腔淋巴结清扫区域外亦然。
- 作者认为术前影像对能否实施前哨淋巴结活检具有预测价值,并凸显其在具挑战性的影像引导手术应用中的关键作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: In muscle-invasive bladder cancer (MIBC), lymph node invasion has proven to be an independent predictor of disease recurrence and cancer-specific survival. We evaluated the feasibility of targeting the sentinel node (SN) for biopsy in MIBC patients using the hybrid tracer indocyanine green (ICG)- 99m Tc-nanocolloid for simultaneous radioguidance and fluorescence guidance. METHODS: Twenty histologically confirmed cN0M0 MIBC patients (mean age, 63.3 years; range, 30-82 years), scheduled for radical cystectomy with SN biopsy and extended pelvic lymph node dissection (ePLND), were prospectively included. Twelve patients were operated on following neoadjuvant chemotherapy. The patients received lymphoscintigraphy as well as SPECT/CT after 4 transurethral injections of ICG- 99m Tc-nanocolloid (mean, 208 MBq; range, 172-229 MBq) around the tumor/scar in the detrusor muscle of the bladder on the day before radical cystectomy. Sentinel node resection was performed under radioguidance and fluorescence guidance. RESULTS: Nineteen patients could be analyzed. On preoperative imaging, SNs could be identified in 10 patients (53%; mean, 1.6 SN/patient), which revealed drainage pathways outside the ePLND in 20% of the patients. Interesting to note is that 2 patients (10%) with preoperative nonvisualization displayed fluorescent and radioactive SNs during surgery. Location of the primary tumor near the left lateral side of the bladder seemed to be a factor for nonvisualization. Nodal harvesting with ePLND varied among patients (mean, 23.3). Histopathology confirmed tumor-positive nodes in 4 (21%) of all patients. In the 2 patients where an SN could be identified, the ePLND specimens were tumor-negative. All patients with tumor-positive nodes had advanced disease (stage III). CONCLUSION: Sentinel node biopsy in bladder cancer using the hybrid tracer ICG- 99m Tc-nanocolloid is feasible, and preoperative imaging is predictive for the ability to perform SN biopsy in 83% of the patients who displayed an SN. In patients with a successful preoperative SN mapping using lymphoscintigraphy and SPECT/CT, the intraoperative SN guidance and detection were effective, even outside the ePLND area. As such, this study underscores the critical role that preoperative imaging plays in challenging image-guided surgery applications.
引用
- Rietbergen DDD, van Gennep EJ, KleinJan GH, et al. Evaluation of the Hybrid Tracer Indocyanine Green- 99m Tc-Nanocolloid for Sentinel Node Biopsy in Bladder Cancer-A Prospective Pilot Study. Clin Nucl Med. 2022. PMID: 35713891. doi:10.1097/RLU.0000000000004301
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。